vs
Side-by-side financial comparison of Johnson & Johnson (JNJ) and TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD (TSM). Click either name above to swap in a different company.
TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD is the larger business by last-quarter revenue ($35.5B vs $24.6B, roughly 1.4× Johnson & Johnson). TAIWAN SEMICONDUCTOR MANUFACTURING CO LTD runs the higher net margin — 50.5% vs 20.8%, a 29.7% gap on every dollar of revenue.
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 48 on the 2025 Fortune 500 list of the largest United States corporations. In 2025, the company was ranked 42th in the Forbes Global 2000.
Taiwan Semiconductor Manufacturing Company (TSMC) is the world's largest dedicated independent semiconductor foundry, headquartered in Hsinchu, Taiwan. It manufactures advanced logic chips on contract for fabless customers including Apple, NVIDIA, AMD, Qualcomm, and Broadcom, and leads the industry in leading-edge process nodes (3nm/5nm/7nm).
JNJ vs TSM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $24.6B | $35.5B |
| Net Profit | $5.1B | $17.9B |
| Gross Margin | 67.6% | 66.2% |
| Operating Margin | 20.2% | 58.0% |
| Net Margin | 20.8% | 50.5% |
| Revenue YoY | 9.1% | — |
| Net Profit YoY | 49.1% | — |
| EPS (diluted) | $2.08 | $111.55 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $35.5B | ||
| Q4 25 | $24.6B | $32.7B | ||
| Q3 25 | $24.0B | $30.7B | ||
| Q2 25 | $23.7B | $28.9B | ||
| Q1 25 | $21.9B | $26.0B | ||
| Q4 24 | $22.5B | $88.3B | ||
| Q3 24 | $22.5B | — | ||
| Q2 24 | $22.4B | — |
| Q1 26 | — | $17.9B | ||
| Q4 25 | $5.1B | $15.8B | ||
| Q3 25 | $5.2B | $14.0B | ||
| Q2 25 | $5.5B | $12.3B | ||
| Q1 25 | $11.0B | $11.2B | ||
| Q4 24 | $3.4B | $35.3B | ||
| Q3 24 | $2.7B | — | ||
| Q2 24 | $4.7B | — |
| Q1 26 | — | 66.2% | ||
| Q4 25 | 67.6% | 62.3% | ||
| Q3 25 | 69.6% | 59.5% | ||
| Q2 25 | 67.9% | 58.6% | ||
| Q1 25 | 66.4% | 58.8% | ||
| Q4 24 | 68.3% | 56.1% | ||
| Q3 24 | 69.0% | — | ||
| Q2 24 | 69.4% | — |
| Q1 26 | — | 58.0% | ||
| Q4 25 | 20.2% | 53.9% | ||
| Q3 25 | 31.2% | 50.6% | ||
| Q2 25 | 27.3% | 49.6% | ||
| Q1 25 | 62.3% | 48.5% | ||
| Q4 24 | 17.3% | 45.7% | ||
| Q3 24 | 14.9% | — | ||
| Q2 24 | 25.6% | — |
| Q1 26 | — | 50.5% | ||
| Q4 25 | 20.8% | 48.3% | ||
| Q3 25 | 21.5% | 45.7% | ||
| Q2 25 | 23.3% | 42.7% | ||
| Q1 25 | 50.2% | 43.1% | ||
| Q4 24 | 15.2% | 40.0% | ||
| Q3 24 | 12.0% | — | ||
| Q2 24 | 20.9% | — |
| Q1 26 | — | $111.55 | ||
| Q4 25 | $2.08 | $98.45 | ||
| Q3 25 | $2.12 | $87.20 | ||
| Q2 25 | $2.29 | $76.80 | ||
| Q1 25 | $4.54 | $69.70 | ||
| Q4 24 | $1.41 | $1.36 | ||
| Q3 24 | $1.11 | — | ||
| Q2 24 | $1.93 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $20.1B | — |
| Total DebtLower is stronger | $41.4B | — |
| Stockholders' EquityBook value | $81.5B | — |
| Total Assets | $199.2B | — |
| Debt / EquityLower = less leverage | 0.51× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $20.1B | — | ||
| Q3 25 | $18.6B | — | ||
| Q2 25 | $18.9B | — | ||
| Q1 25 | $38.8B | — | ||
| Q4 24 | $24.5B | $64.9B | ||
| Q3 24 | $20.3B | — | ||
| Q2 24 | $25.5B | — |
| Q1 26 | — | — | ||
| Q4 25 | $41.4B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $32.4B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $81.5B | — | ||
| Q3 25 | $79.3B | — | ||
| Q2 25 | $78.5B | — | ||
| Q1 25 | $78.1B | — | ||
| Q4 24 | $71.5B | $130.5B | ||
| Q3 24 | $70.2B | — | ||
| Q2 24 | $71.5B | — |
| Q1 26 | — | — | ||
| Q4 25 | $199.2B | — | ||
| Q3 25 | $192.8B | — | ||
| Q2 25 | $193.4B | — | ||
| Q1 25 | $193.7B | — | ||
| Q4 24 | $180.1B | $204.1B | ||
| Q3 24 | $178.3B | — | ||
| Q2 24 | $181.1B | — |
| Q1 26 | — | — | ||
| Q4 25 | 0.51× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.45× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $7.3B | — |
| Free Cash FlowOCF − Capex | $5.5B | — |
| FCF MarginFCF / Revenue | 22.3% | — |
| Capex IntensityCapex / Revenue | 7.5% | — |
| Cash ConversionOCF / Net Profit | 1.43× | — |
| TTM Free Cash FlowTrailing 4 quarters | $19.7B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $7.3B | — | ||
| Q3 25 | $9.2B | — | ||
| Q2 25 | $3.9B | — | ||
| Q1 25 | $4.2B | — | ||
| Q4 24 | $7.0B | $55.7B | ||
| Q3 24 | $8.0B | — | ||
| Q2 24 | $5.6B | — |
| Q1 26 | — | — | ||
| Q4 25 | $5.5B | — | ||
| Q3 25 | $8.0B | — | ||
| Q2 25 | $2.8B | — | ||
| Q1 25 | $3.4B | — | ||
| Q4 24 | $5.4B | $26.5B | ||
| Q3 24 | $7.0B | — | ||
| Q2 24 | $4.7B | — |
| Q1 26 | — | — | ||
| Q4 25 | 22.3% | — | ||
| Q3 25 | 33.4% | — | ||
| Q2 25 | 11.9% | — | ||
| Q1 25 | 15.4% | — | ||
| Q4 24 | 23.8% | 30.1% | ||
| Q3 24 | 31.0% | — | ||
| Q2 24 | 20.7% | — |
| Q1 26 | — | — | ||
| Q4 25 | 7.5% | — | ||
| Q3 25 | 4.8% | — | ||
| Q2 25 | 4.4% | — | ||
| Q1 25 | 3.6% | — | ||
| Q4 24 | 7.2% | 33.0% | ||
| Q3 24 | 4.6% | — | ||
| Q2 24 | 4.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.43× | — | ||
| Q3 25 | 1.78× | — | ||
| Q2 25 | 0.70× | — | ||
| Q1 25 | 0.38× | — | ||
| Q4 24 | 2.04× | 1.58× | ||
| Q3 24 | 2.97× | — | ||
| Q2 24 | 1.20× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JNJ
| Other | $14.2B | 58% |
| Immunology | $2.5B | 10% |
| Orthopaedics | $1.5B | 6% |
| Neuroscience | $1.4B | 6% |
| Cardiovascular | $1.4B | 6% |
| Surgery | $1.1B | 4% |
| Pulmonary Hypertension | $865.0M | 4% |
| Cardiovascular Metabolism Other | $794.0M | 3% |
| Vision | $531.0M | 2% |
| Infectious Diseases | $303.0M | 1% |
TSM
Segment breakdown not available.
